Daptomycin

In plain language

Daptomycin is an intravenous antibiotic for serious infections caused by resistant Gram-positive bacteria, including MRSA. It is sold as Cubicin and as generics.

It was found in soil bacteria by scientists at Eli Lilly in the 1980s and finished by Cubist Pharmaceuticals. Its ring of 13 amino acids carries a fatty tail that punches into bacterial membranes and opens holes, killing the cell in a way unlike any other antibiotic. Its main caution is muscle damage, monitored with a weekly blood test.

For students

Daptomycin is a cyclic 13-residue lipopeptide (about 1,621 Da) from Streptomyces roseosporus, discovered by Eli Lilly in the 1980s (LY146032) and revived and registered by Cubist as Cubicin in 2003. Its C-terminal decanoic acid tail inserts into Gram-positive membranes, where calcium-dependent oligomerization forms ion-conducting channels, collapsing membrane potential; lethality is rapid and independent of cell division.

Resistance via altered membrane composition (mprF mutations increasing lysyl-phosphatidylglycerol) emerges on therapy, and daptomycin is inactivated by lung surfactant, precluding pneumonia use. Pivotal trials established non-inferiority to standard therapy in complicated skin infections and Staphylococcus aureus bacteremia; the latter remains a debated indication where beta-lactams often outperform it for uncomplicated bacteremia, and higher doses are increasingly used for persistent MRSA bacteremia and endocarditis.

For researchers and instructors

Biochemistry. The calcium-dependent anionic-to-cationic transition of the peptide ring is a distinctive structural trigger; membrane depolarization rather than a specific protein target makes cross-resistance with other classes minimal.

Pharmacology. Once-daily dosing (4-6 mg/kg, up to 8-10 mg/kg off-label for persistent bacteremia); creatine phosphokinase monitoring weekly for myopathy; reduced efficacy with concurrent statins is a practical interaction point; pulmonary use is contraindicated by surfactant inactivation.

Human evidence. Registration trials in cSSSI (n=1,092) and S. aureus bacteremia/endocarditis (n=246) established non-inferiority; subsequent comparative observational data and trial-level analyses (e.g., the CAMERA2 trial combining high-dose daptomycin with antistaphylococcal penicillins) inform modern persistent-bacteremia practice.

Teaching point. The exemplar of "rediscovery" pharmacology: a shelved 1980s molecule revived by a biotech and now a cornerstone anti-MRSA agent.